Systematic review examines CMV management in children with HSCT, highlighting evidence gaps and future directions.
Cytomegalovirus (CMV) is one of the most important infectious causes of morbidity and mortality in children undergoing haematopoietic stem cell transplant (HSCT). However, the evidence for preventing and treating CMV disease in children in this context remains limited. We sought to review the current available evidence regarding the prevention and management of CMV infection and disease in children with HSCT and propose future research areas which could better inform evidence‐based management.
No takes yet. Share an insight, caveat, or question.
Fusani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: